{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:17:44Z","timestamp":1789579064872,"version":"build-2803163510"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ijid.2025.108065","type":"journal-article","created":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T04:54:20Z","timestamp":1757825660000},"page":"108065","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Can 6-month long regimens become the standardized treatment for MDR-TB globally?"],"prefix":"10.1016","volume":"160","author":[{"given":"Caterina","family":"Davoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ciccarone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bertoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Calamelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0706-7562","authenticated-orcid":false,"given":"Benedetta","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Matteelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2025.108065_bib0001","series-title":"WHO bacterial priority pathogens list 2024: bacterial pathogens of public health importance, to guide research, development, and strategies to prevent and control antimicrobial resistance","year":"2024"},{"key":"10.1016\/j.ijid.2025.108065_bib0002","series-title":"Global tuberculosis report","year":"2024"},{"key":"10.1016\/j.ijid.2025.108065_bib0003","article-title":"A Comprehensive Review on Long vs. Short Regimens in Multidrug-Resistant Tuberculosis (MDR-TB) under Programmatic Management of Drug-Resistant Tuberculosis (PMDT)","volume":"16","author":"Karnan","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.ijid.2025.108065_bib0004","series-title":"Update","article-title":"WHO consolidated guidelines on tuberculosis. Module 4: treatment \u2011 drugresistant tuberculosis treatment","year":"2022"},{"key":"10.1016\/j.ijid.2025.108065_bib0005","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of highly drug-resistant pulmonary tuberculosis","volume":"382","author":"Conradie","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2025.108065_bib0006","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa2119430","article-title":"Bedaquiline-Pretomanid-Linezolid regimens for drug-resistant tuberculosis","volume":"387","author":"Conradie","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2025.108065_bib0007","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S2213-2600(23)00389-2","article-title":"Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial","volume":"12","author":"Nyang\u2019wa","year":"2024","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ijid.2025.108065_bib0008","series-title":"WHO consolidated operational handbook on tuberculosis: module 4: treatment and care","year":"2025"},{"key":"10.1016\/j.ijid.2025.108065_bib0009","series-title":"Key updates to the treatment of drugresistant tuberculosis: rapid communication, June 2024","year":"2024"},{"key":"10.1016\/j.ijid.2025.108065_bib0010","unstructured":"ClinicalTrials.gov, Tuberculosis BEAT (NCT04062201): Building Evidence for. Advancing New Treatment for rifampicin Resistant Tuberculosis (RR-TB) comparing a short course of treatment (containing bedaquiline, delamanid and linezolid) with the current South African standard of care [Web site], https:\/\/clinicaltrials.gov\/study\/NCT04062201."},{"key":"10.1016\/j.ijid.2025.108065_bib0011","series-title":"WHO consolidated guidelines on tuberculosis. Module 5: management of tuberculosis in children and adolescents","year":"2022"},{"key":"10.1016\/j.ijid.2025.108065_bib0012","article-title":"Multidrug-resistant tuberculosis in children: a practical update on epidemiology, diagnosis, treatment and prevention","volume":"36","author":"Gaensbauer","year":"2024","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"10.1016\/j.ijid.2025.108065_bib0013","doi-asserted-by":"crossref","first-page":"655","DOI":"10.5588\/ijtld.23.0164","article-title":"Community perspective on child-friendly medications for drug-resistant TB: importance, priorities and advocacy","volume":"27","author":"Viljoen","year":"2023","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijid.2025.108065_bib0014","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S1473-3099(23)00349-3","article-title":"Children deserve simple, short, safe, and effective treatment for rifampicin-resistant tuberculosis","volume":"23","author":"Garcia-Prats","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2025.108065_bib0015","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S2352-4642(24)00330-4","article-title":"Characteristics of children and adolescents with multidrug-resistant and rifampicin-resistant tuberculosis and their association with treatment outcomes: a systematic review and individual participant data meta-analysis","volume":"9","author":"Garcia-Prats","year":"2025","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.ijid.2025.108065_bib0016","unstructured":"IMPAACT Network. IMPAACT 2034: A Phase I study of the pharmacokinetics, safety, and acceptability of a single dose of pretomanid added to an optimized background regimen in children with rifampicin-resistant tuberculosis [Internet], https:\/\/www.impaactnetwork.org\/studies\/impaact2034."},{"key":"10.1016\/j.ijid.2025.108065_bib0017","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0305930","article-title":"Pharmaceutical cost dynamics for the treatment of rifampicin-resistant tuberculosis in children and adolescents in South Africa, India, and the Philippines","volume":"19","author":"Wilkinson","year":"2024","journal-title":"PLOS One"},{"key":"10.1016\/j.ijid.2025.108065_bib0018","doi-asserted-by":"crossref","first-page":"371","DOI":"10.5588\/ijtld.23.0031","article-title":"Best practices for the care of pregnant people living with TB","volume":"27","author":"Maugans","year":"2023","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijid.2025.108065_bib0019","series-title":"Pretomanid [prescribing information]","year":"2019"},{"key":"10.1016\/j.ijid.2025.108065_bib0020","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1111\/bcp.15380","article-title":"Bedaquiline exposure in pregnancy and breastfeeding in women with rifampicin-resistant tuberculosis","volume":"88","author":"Court","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ijid.2025.108065_bib0021","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.3390\/pharmaceutics15041228","article-title":"Infant exposure to antituberculosis drugs via breast milk and assessment of potential adverse effects in breastfed infants: critical review of data","volume":"15","author":"Algharably","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijid.2025.108065_bib0022","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1093\/cid\/ciaa189","article-title":"Maternal and infant outcomes among pregnant women treated for multidrug\/rifampicin-resistant tuberculosis in South Africa","volume":"72","author":"Loveday","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2025.108065_bib0023","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/cid\/ciad445","article-title":"Pregnancy and birth outcomes in patients with multidrug-resistant tuberculosis treated with regimens that include new and repurposed drugs","volume":"78","author":"Lotia Farrukh","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2025.108065_bib0024","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1097\/INF.0000000000003069","article-title":"Outcomes of children born to pregnant women with drug-resistant tuberculosis treated with novel drugs in Khayelitsha, South Africa: A report of five patients","volume":"40","author":"Acquah","year":"2021","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijid.2025.108065_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e37547","article-title":"Pregnancy related adverse events and congenital disorders associated with fluoroquinolones: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System (FAERS)","volume":"10","author":"Xiang","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.ijid.2025.108065_bib0026","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12879-020-05749-2","article-title":"HIV infection and multidrug resistant tuberculosis: a systematic review and meta-analysis","volume":"21","author":"Sultana","year":"2021","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijid.2025.108065_bib0027","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1056\/NEJMoa2400327","article-title":"Oral regimens for rifampin-resistant, fluoroquinolone-susceptible tuberculosis","volume":"392","author":"Guglielmetti","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2025.108065_bib0028","unstructured":"European AIDS clinical society (EACS). EACS guidelines. version 12.1, 2024, https:\/\/eacs.sanfordguide.com."},{"key":"10.1016\/j.ijid.2025.108065_bib0029","doi-asserted-by":"crossref","first-page":"3482","DOI":"10.1007\/s00415-022-11052-8","article-title":"Global morbidity and mortality of central nervous system tuberculosis: a systematic review and meta-analysis","volume":"269","author":"Navarro-Flores","year":"2022","journal-title":"J Neurol"},{"key":"10.1016\/j.ijid.2025.108065_bib0030","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2021-245612","article-title":"Sterile tuberculous granuloma in a patient with XDR-TB treated with bedaquiline, pretomanid and linezolid","volume":"14","author":"Howell","year":"2021","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.ijid.2025.108065_bib0031","doi-asserted-by":"crossref","first-page":"11902","DOI":"10.1039\/C8RA00984H","article-title":"Bedaquiline has potential for targeting tuberculosis reservoirs in the central nervous system","volume":"8","author":"Pamreddy","year":"2018","journal-title":"RSC Adv"},{"key":"10.1016\/j.ijid.2025.108065_bib0032","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1093\/jac\/dkac067","article-title":"Pharmacokinetics of bedaquiline in cerebrospinal fluid (CSF) in patients with pulmonary tuberculosis (TB)","volume":"77","author":"Upton","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2025.108065_bib0033","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1093\/cid\/ciab992","article-title":"Cycloserine and linezolid for tuberculosis meningitis: pharmacokinetic evidence of potential usefulness","volume":"75","author":"Kempker","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2025.108065_bib0034","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s40262-024-01363-6","article-title":"Predictions of bedaquiline central nervous system exposure in patients with tuberculosis meningitis using physiologically based pharmacokinetic modeling","volume":"63","author":"Mehta","year":"2024","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijid.2025.108065_bib0035","doi-asserted-by":"crossref","first-page":"6657","DOI":"10.1038\/s41467-024-50989-4","article-title":"Dynamic PET reveals compartmentalized brain and lung tissue antibiotic exposures of tuberculosis drugs","volume":"15","author":"Chen","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijid.2025.108065_bib0036","doi-asserted-by":"crossref","first-page":"7974","DOI":"10.1038\/s41467-022-35730-3","article-title":"Dynamic 18F-Pretomanid PET imaging in animal models of TB meningitis and human studies","volume":"13","author":"Mota","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijid.2025.108065_bib0037","doi-asserted-by":"crossref","first-page":"e00913","DOI":"10.1128\/AAC.00913-19","article-title":"Delamanid central nervous system pharmacokinetics in tuberculous meningitis in rabbits and humans","volume":"63","author":"Tucker","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2025.108065_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120655","article-title":"Clofazimine functionalized polymeric nanoparticles for brain delivery in the tuberculosis treatment","volume":"602","author":"de Castro","year":"2021","journal-title":"Int J Pharm"},{"key":"10.1016\/j.ijid.2025.108065_bib0039","article-title":"Concomitant bedaquiline and delamanid therapy in patients with drug-resistant extra-pulmonary tuberculosis in Mumbai, India","volume":"35","author":"Mongia","year":"2024","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"10.1016\/j.ijid.2025.108065_bib0040","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12879-023-08970-x","article-title":"Differential distribution of linezolid in diseased and nondiseased bones in patients with spinal tuberculosis","volume":"24","author":"Li","year":"2024","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijid.2025.108065_bib0041","article-title":"Penetration of linezolid into bone tissue 24 h after administration in patients with multidrug-resistant spinal tuberculosis","volume":"14","author":"Li","year":"2019","journal-title":"PLOS One"},{"key":"10.1016\/j.ijid.2025.108065_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.bjid.2022.102701","article-title":"Use of bedaquiline in spinal osteomyelitis and soft tissue abscess caused by multidrug-resistant Mycobacterium tuberculosis: A case report","volume":"26","author":"De Vito","year":"2022","journal-title":"Braz J Infect Dis"},{"key":"10.1016\/j.ijid.2025.108065_bib0043","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ijid.2019.02.005","article-title":"Antibiotic penetration into bone and joints: an updated review","volume":"81","author":"Thabit","year":"2019","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijid.2025.108065_bib0044","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jctube.2016.03.003","article-title":"Miliary tuberculosis: A new look at an old foe","volume":"3","author":"Sharma","year":"2016","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"10.1016\/j.ijid.2025.108065_bib0045","first-page":"9","article-title":"Drug-resistant tuberculosis and HIV infection: current perspectives","volume":"12","author":"Singh","year":"2020","journal-title":"HIV Aids (Auckl)"},{"key":"10.1016\/j.ijid.2025.108065_bib0046","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/ajd.12053","article-title":"Multidrug resistant miliary tuberculosis during infliximab therapy despite tuberculosis screening","volume":"55","author":"Gin","year":"2014","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.ijid.2025.108065_bib0047","doi-asserted-by":"crossref","first-page":"35","DOI":"10.4103\/lungindia.lungindia_72_23","article-title":"Effect of delamanid on interim outcomes of bacteriological conversion amongst pediatric drug resistant tuberculosis cases in India","volume":"41","author":"Kalawadia","year":"2024","journal-title":"Lung India"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971225002875?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971225002875?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T04:12:46Z","timestamp":1761192766000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971225002875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":47,"alternative-id":["S1201971225002875"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2025.108065","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Can 6-month long regimens become the standardized treatment for MDR-TB globally?","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2025.108065","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}],"article-number":"108065"}}